Canada markets closed
  • S&P/TSX

    -108.35 (-0.48%)
  • S&P 500

    +1.32 (+0.02%)
  • DOW

    -216.74 (-0.55%)

    -0.0018 (-0.24%)

    +0.30 (+0.38%)
  • Bitcoin CAD

    +1,017.05 (+1.09%)
  • CMC Crypto 200

    -44.78 (-2.99%)

    +1.50 (+0.06%)
  • RUSSELL 2000

    -2.82 (-0.14%)
  • 10-Yr Bond

    +0.0750 (+1.68%)
  • NASDAQ futures

    -58.00 (-0.31%)

    +0.56 (+4.53%)
  • FTSE

    -63.41 (-0.76%)
  • NIKKEI 225

    -117.15 (-0.30%)

    -0.0008 (-0.12%)

Global LUM001 Insight and Market Forecast to 2030: Comprehensive Coverage of the Late-stage Emerging Therapies (Phase II) for Alagille Syndrome

Dublin, Dec. 15, 2020 (GLOBE NEWSWIRE) -- The "LUM001 - Emerging Insight and Market Forecast - 2030" report has been added to's offering.

"LUM001- Emerging Insight and Market Forecast - 2030" the report provides comprehensive insights about an investigational product for Alagille syndrome in 7 Major Markets. A detailed picture of the LUM001 in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2020-2030 is provided in this report along with a detailed description of the product.

The product details cover mechanism of action, dosage and administration, route of synthesis, and Research and development activity including regulatory milestones, and other development activities. Further, it also consists of future market assessments inclusive of the market forecast, SWOT analysis, market competitors, and other emerging therapies.


LUM001 is an inhibitor of the apical sodium-dependent bile acid transporter (ASBT), which recycles intestinal bile acids back into the circulation. By reducing serum bile acids with a once-daily oral tablet, LUM001 may offer a novel therapeutic approach for alleviating the severe itching and progressive liver damage associated with many cholestatic liver diseases. LUM001 has received Orphan Drug Designation by the U.S. Food & Drug Administration (FDA) Office of Orphan Product Development in four rare cholestatic liver diseases including primary biliary cirrhosis; progressive familial intrahepatic cholestasis; Alagille syndrome; and primary sclerosing cholangitis.

Scope of the Report

The report provides insights into:

  • A comprehensive product overview including the product description, mechanism of action, dosage and administration, Research and Development activity.

  • Elaborated details on regulatory milestones and other development activities have been provided in this report.

  • The report also highlights the drug research and development activity details across the United States, Europe and Japan.

  • The report also covers the patents information with expiry timeline around LUM001.

  • The report contains forecasted sales for LUM001 till 2030.

  • Comprehensive coverage of the late-stage emerging therapies (Phase II) for Alagille syndrome.

  • The report also features the SWOT analysis with analyst insights and key findings of LUM001.

LUM001 Analytical Perspective

In-depth LUM001 Market Assessment

This report provides a detailed market assessment of LUM001 in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This segment of the report provides forecasted sales data from 2020 to 2030.

LUM001 Clinical Assessment

The report provides the clinical trials information of LUM001 covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights

  • In the coming years, the market scenario for Alagille syndrome is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.

  • The companies and academics are working to assess challenges and seek opportunities that could influence LUM001 dominance. The therapies under development are focused on novel approaches to treat/improve the disease condition.

  • Other emerging products for Alagille syndrome are giving market competition to LUM001 and launch of late-stage emerging therapies in the near future will significantly impact the market.

  • A detailed description of regulatory milestones, development activities, and some key findings provide the current development scenario of LUM001.

  • The in-depth analysis of the forecasted sales data of LUM001 from 2020 to 2030 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the LUM001.


Key Questions Answered

  • Which company is developing LUM001 along with the phase of the clinical study?

  • What is the technology utilized in the development of LUM001?

  • What is the product type, route of administration and mechanism of action of LUM001?

  • What is the clinical trial status of the study and study completion date?

  • What are the key collaborations, mergers and acquisitions, licensing and other activities related to the LUM001 development?

  • What are the key designations that have been granted to LUM001?

  • What is the forecasted market scenario of LUM001?

  • What is the history of LUM001 and what is its future?

  • What is the forecasted sales of LUM001 in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?

  • What are the other emerging products available and how these are giving competition to LUM001?

  • Which are the late-stage emerging therapies under development for the treatment of the PPD?

Key Topics Covered:

1. Drug Overview
1.1. Product Detail
1.2. Mechanism of Action
1.3. Dosage and Administration
1.4. Research and development activity
1.4.1. Clinical Development
1.4.2. Safety and Efficacy
1.5. Other Development Activities

2. Market Assessment
2.1. 7MM Market Analysis
2.2. The United States Market
2.3. Germany Market
2.4. France Market
2.5. Italy Market
2.6. Spain Market
2.7. United Kingdom Market
2.8. Japan Market

3. SWOT Analysis

4. Analyst Views

5. Market Competitors

6. Other Emerging Therapies

7. Appendix

For more information about this report visit

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

CONTACT: CONTACT: Laura Wood, Senior Press Manager For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900